中药治疗过敏性鼻炎的多靶点机制综述
该综述系统总结了过敏性鼻炎的多因素发病机制及中药治疗潜力,基于PubMed等数据库近五年文献。中药可通过调控NF-κB、GATA3、紧密连接蛋白及肠道菌群等多靶点改善症状,但多数机制证据来自动物模型,人体转化证据有限。
要点
- 中药复方如玉屏风散在临床应用中显示缓解过敏性鼻炎症状的疗效。
- 中药可调控Th2极化、上皮屏障及菌群等AR相关免疫紊乱。
- 多数机制证据来自动物模型,需大规模多中心临床试验验证。
核心结论
- 中药通过整体多靶点调控机制在过敏性鼻炎治疗中显示临床前潜力,但需进一步人体研究验证。
研究设计与样本
- 系统检索PubMed、Web of Science、EMBASE、Cochrane Library、万方及CNKI等数据库,纳入近五年(2020-2025)原始临床研究、观察性研究、随机对照试验、荟萃分析及经典机制早期研究。
主要发现
- 过敏性鼻炎发病涉及Th2细胞极化、黏膜上皮屏障损伤、微生物群失调及神经免疫相互作用。
- 中药可调控NF-κB和GATA3等转录因子、恢复紧密连接蛋白(如ZO-1和occludin)及调节肠道菌群增加短链脂肪酸产生。
- 一项随机对照试验(n=60)报告甘草鼻腔冲洗显著改善SNOT-22评分(从27.9±15.5降至13.2±9.6,p<0.001)并降低鼻气道阻力(p<0.001),效果优于皮质类固醇或生理盐水冲洗。
关键数值与推荐
- 纳入标准包括近五年(2020-2025)发表的AR发病机制及中药治疗相关原创临床研究、观察性研究、随机对照试验和荟萃分析。
- 排除摘要、会议论文、观点文章、非同行评议文章、方法学质量低及不相关研究。
- 甘草鼻腔冲洗的随机对照试验(n=60)显示SNOT-22评分从27.9±15.5降至13.2±9.6(p<0.001)且鼻气道阻力降低(p<0.001)。
临床怎么用
- 中药可作为过敏性鼻炎的单药或联合西药治疗选择,基于初步安全性和有效性证据。
- 临床可参考玉屏风散等经典复方及甘草鼻腔冲洗等局部治疗方法。
局限性
- 多数机制研究来自动物模型,直接转化至人体的证据有限。
- 需要大规模多中心临床试验及先进生物技术推动中药标准化和全球认可。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
ETHNOPHARMACOLOGICAL RELEVANCE: Allergic rhinitis (AR) is a prevalent chronic inflammatory condition mediated by immunoglobulin E (IgE). In traditional Chinese medicine (TCM), AR is categorized under the term "bi qiu", with its core pathogenesis attributed to dysfunction of the lung, spleen, and kidney, compounded by external pathogenic invasion. Chinese herbal formulas, such as Yupingfeng San (Jade Wind Screen Powder), documented in the Danxi Xinfa, have demonstrated therapeutic efficacy in alleviating AR symptoms, supported by centuries of clinical application in China. AIM OF THE STUDY: This review systematically synthesizes recent advances in the multifactorial pathogenesis of AR and evaluates the therapeutic potential of TCM based on clinical efficacy data and mechanistic studies. It further elucidates the capacity of TCM to modulate AR-associated immune dysregulation, epithelial barrier dysfunction, and microbial imbalance through multi-target mechanisms. By doing so, the review establishes a theoretical framework supporting the application of TCM in AR management and proposes innovative TCM-based strategies to overcome limitations associated with conventional treatments. MATERIALS AND METHODS: This paper provides a systematic summary of the pathogenesis of allergic rhinitis (AR) and evaluates the clinical efficacy and molecular mechanisms of traditional Chinese medicine (TCM) in the treatment of AR. The findings are based on a comprehensive literature search conducted in PubMed, Web of Science, EMBASE, Cochrane Library, Wanfang Database, and China National Knowledge Infrastructure (CNKI). The search strategy employed keywords including "allergic rhinitis," "pathogenesis," "traditional Chinese medicine," "Chinese herbal medicine," "herbal medicine," and "active components of Chinese medicine.""treatment," "immunotherapy," and "biologics" in various combinations. INCLUSION CRITERIA: ① Original clinical studies, observational studies, randomized controlled trials (RCTs), and meta-analyses related to the topic.② Articles published in the last five years (2020-2025) on AR pathogenesis and TCM treatment, with seminal earlier studies on classical mechanisms (e.g., Th1/Th2 imbalance) also included to provide foundational context.③Research on the mechanisms, treatment strategies, or therapeutic effects of Traditional Chinese and Western medicine in AR. EXCLUSION CRITERIA: ① Abstracts, conference proceedings, opinion pieces, or non-peer-reviewed articles. ② Studies with low methodological quality (e.g., lacking control groups). ③ Irrelevant studies or those focusing on unrelated diseases.All plant names have been verified against The World Flora Online (http://www.worldfloraonline.org, accessed February 25, 2026) to ensure compliance with current taxonomic standards. A PRISMA flowchart documenting the literature screening process has been provided in the Supplementary Materials (Figure S1). RESULTS: The pathogenesis of AR involves Th2 cell polarization, impairment of the mucosal epithelial barrier, dysbiosis of the microbiota, and neuro-immune interactions. Conventional treatments are often associated with limitations, including adverse effects and high costs. TCM has been shown to ameliorate AR symptoms through mechanisms such as regulating transcription factors including NF-κB and GATA3, restoring epithelial tight junction proteins (e.g., ZO-1 and occludin), and modulating gut microbiota composition, including increasing the production of short-chain fatty acids (SCFAs). Clinical studies have provided preliminary evidence for the safety and efficacy of TCM, both as monotherapy and in combination with Western medicine, for the management of AR.However, most mechanistic insights are derived from animal models, and direct translational evidence to human applications remains limited. Notably, a randomized controlled trial (n = 60) reported that nasal lavage with Glycyrrhizae Radix et Rhizoma (licorice) significantly improved SNOT-22 scores (from 27.9 ± 15.5 to 13.2 ± 9.6, p < 0.001) and reduced nasal airway resistance (p < 0.001), with effects superior to those of corticosteroid or saline lavage. CONCLUSION: TCM demonstrates preclinical potential in the treatment of AR, which is characterized by multifactorial etiology, through holistic and multi-target regulatory mechanisms. Further validation in human studies is needed. Future research should prioritize large-scale, multi-center clinical trials and leverage advanced biotechnological approaches to facilitate the standardization and global acceptance of TCM in allergy management.
引用
- Liu J, Pang S, Lu Y, et al. Multi-target mechanisms of Chinese herbal medicine in the treatment of allergic rhinitis. J Ethnopharmacol. 2026. PMID: 42061564. doi:10.1016/j.jep.2026.121704
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。